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Edited by Beat ImhofAbstract ADAMTS13 is gaining attention, because its deﬁ-
ciency causes thrombotic thrombocytopenic purpura. Although
its regulatory mechanism is not fully understood, we wondered
if hepatic stellate cells (HSCs) play a role, because ADAMTS13
mRNA is exclusively expressed in the liver and primarily in
HSCs. Plasma ADAMTS13 activity was markedly reduced in
dimethylnitrosamine-treated rats, where HSC apoptosis is an
essential event, but not in carbon tetrachloride- or thioaceta-
mide-treated rats without HSC apoptosis. Furthermore, plasma
ADAMTS13 activity was also reduced in 70% hepatectomized
rats, where HSC loss occurs. These results suggest that HSC
may be involved in the regulation of plasma ADAMTS13 activ-
ity.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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A disintegrin-like and metalloproteinase with thrombospon-
din type-1 motifs 13 (ADAMTS13) cleaves the multimers of
von Willebrand factor (VWF) into smaller sizes [1]. VWF is
synthesized as unusually large multimers of VWF (UL-
VWF) in vascular endothelial cells [2]. After being released
into plasma, UL-VWFs are rapidly cleaved by ADAMTS13
[1]. ADAMTS 13 is gaining attention, because it is unveiled
that a defect in ADAMTS13 activity increases UL-VWFs in
the plasma, causes platelet thrombosis under a high sheer
stress, and ﬁnally results in Upshaw-Schulman syndrome by
genetic mutations or thrombotic thrombocytopenic purpura
(TTP) via inhibitory autoantibodies [3–5]; TTP is an important
hematological illness characterized by thrombocytopenia,
microangiopathic hemolytic anemia, fever, renal dysfunction,
and central nervous system ischemia resulting from the forma-
tion of platelet thrombi within the microvasculature [3]. Vari-*Corresponding author. Address: Department of Laboratory Medi-
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doi:10.1016/j.febslet.2007.03.029ous levels of decreasing plasma ADAMTS13 activity were
observed in other conditions such as hemolytic uremic syn-
drome [6], but the regulatory mechanism of this enzyme activ-
ity is not yet fully understood.
Recent studies revealed that ADAMTS13 mRNA is exclu-
sively expressed in the liver, which may suggest that the liver
is a major site involved in the synthesis of ADAMTS13 [7–
9]. Moreover, it has been identiﬁed that ADAMTS13 mRNA
is primarily expressed in hepatic stellate cells among the liver
cells, suggesting that these cells are the major cells to synthesize
ADAMTS13 [10,11]. Thus, we wondered whether damage to
hepatic stellate cells might be one of the mechanisms of
decreasing plasma ADAMTS13 activity.
Many chemical agents cause liver injury. Among them, we
previously reported that dimethylnitrosamine (DMN) selec-
tively causes the apoptosis of hepatic stellate cells in rats
[12]. With this evidence, we wondered if plasma ADAMTS13
activity would be reduced in DMN-induced acute liver injury
in rats, in comparison with carbon tetrachloride (CCl4)-in-
duced acute liver injury in rats, where the apoptosis of hepatic
stellate cells is not an essential event [12].2. Materials and methods
Animals. Male Sprague–Dawley rats (Shizuoka Laboratory Animal
Center, Shizuoka, Japan) were fed a standard pelleted diet and water
ad libitum, and used in all experiments. They were housed in groups
of three or four per cage under normal laboratory conditions. All ani-
mals received human care in compliance with the Institution’s Guide-
lines of the University of Tokyo and the National Institutes of Health
Guidelines.
Induction of acute liver injury by DMN, CCl4 or thioacetamide
(TAA) and plasma supplementation in rats. Rats (weighing 170–
190 g) received an intraperitoneal injection of 10, 25 or 50 mg/kg body
weight of DMN as a 2.5% solution in saline and were sacriﬁced at var-
ious times after the injection up to 24 h [12]. In some DMN-treated
rats, 2 ml of normal rat plasma was administered at 4 and 8 h after
the DMN injection through inguinal vein, and rats were sacriﬁced at
12 h. To induce acute liver injury by CCl4 or TAA, rats (weighing
170–190 g) received a subcutaneous injection of 2.0 mg/kg body weight
of CCl4 as a 20% solution in olive oil and were sacriﬁced at 24 h after
the injection [12], or intraperitoneal injections of 300 mg/kg body
weight of TAA in saline, twice at 24-h intervals, and were sacriﬁced
at 48 h after the ﬁrst injection [13].
Blood collection and separation of plasma and serum. Blood was col-
lected through the inferior vena cava with a 21G needle and plastic syr-
inge. Blood at 1.8 ml was mixed with 0.2 ml of 3.2% sodium citrate,
and after measuring the platelet count, the rest of the citrated bloodblished by Elsevier B.V. All rights reserved.
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non-citrated blood.
Measurement of ADAMTS13 activity. ADAMTS13 activity in the
plasma was measured using an ADAMTS13 activity ELISA kit (Japan
Clinical Laboratories Inc., Kyoto) [14].
Measurement of platelet count and liver function. The platelet count
and serum levels of alanine aminotransferase (ALT) and albumin
(Alb) were determined using an automated analyzer (Hitachi 7170;
Hitachi Instruments Service Co., Ltd., Tokyo, Japan).
Partial hepatectomy. Partial hepatectomy (70%) was performed in
rats according to the methods described by Higgins and Anderson
[15]. Control rats underwent sham operations.
Statistical analysis. When indicated, statistical analysis was per-
formed by Student’s t-test, and P < 0.05 was considered signiﬁcant.Fig. 1. (A) Plasma ADAMTS13 activity in DMN-, CCl4- or TAA-
treated rats. Rats received an injection of 50 mg/kg body weight of
DMN or an injection of 2.0 mg/kg body weight of CCl4 and were
sacriﬁced at 24 h after the injection, or intraperitoneal injections of
300 mg/kg body weight of TAA in saline, twice at 24-h intervals, and
were sacriﬁced at 48 h after the ﬁrst injection. ADAMTS13 activity
was measured in the plasma using an ADAMTS13 activity ELISA kit.
Columns and bars represent the means ± S.D. of eight samples for
DMN-terated rats and of four samples for CCl4- or TAA-treated rats.
An asterisk indicates a signiﬁcant diﬀerence between untreated control
and DMN-treated rats (P < 0.05 or higher degree of signiﬁcance). (B)
Dose response of the eﬀect of DMN on plasma ADAMTS13 activity in
rats. Rats received an injection of 10, 25, 50 mg/kg body weight of
DMN and were sacriﬁced at 24 h after the injection. ADAMTS13
activity was measured in the plasma as described above. Bars represent
the mean ± S.D. of eight samples.
Table 1
Liver function and platelet count in rats treated with hepatotoxins
ALT (IU/L) Alb (g/dL) Platelets (·104)
Control 39.2 ± 4.2 2.5 ± 0.0 102.2 ± 18.7
DMN-treated 1608.0 ± 993.4 2.5 ± 0.2 13.6 ± 7.5
CCl4-treated 674.5 ± 414.3 2.4 ± 0.1 85.6 ± 5.4
TAA-treated 1994.5 ± 836.2 2.3 ± 0.2 85.3 ± 18.4
Each value represents the mean ± S.D. of eight samples for control or
DMN-treated rats, and of four samples for CCl4-treated or TAA-
treated rats.3. Results and discussion
We previously demonstrated apoptosis of hepatic stellate
cells occurs in rats with acute liver injury induced by DMN un-
der electron microscopic observation, which is followed by
sinusoidal endothelial cell degeneration and, thereafter, hepa-
tocyte necrosis [12]. Fibrin thrombi appear in the sinusoids
as well as in the necrotic area after the manifestation of hepa-
tocyte necrosis [12]. In contrast, hepatocyte degeneration is
ﬁrstly seen without hepatic stellate cell apoptosis and ﬁbrin
thrombi in the sinusoids of rats with acute liver injury induced
by CCl4 [12]. The fact that hepatic stellate cell apoptosis is not
accompanied in CCl4-induced acute liver injury in rats was
reported elsewhere [16–18]. Thus, DMN-induced acute liver
injury is distinct from CCl4-induced injury in that hepatic
stellate cells undergo apoptosis. In this study, we induced acute
liver injury in rats with DMN or CCl4, as we previously de-
scribed [12], and determined plasma ADAMTS13 activity in
those rats. As demonstrated in Fig. 1A, plasma ADAMTS13
activity was markedly reduced in rats treated with 50 mg/kg
body weight of DMN compared to untreated rats at 24 h after
the injection. In contrast, plasma ADAMTS13 activity was not
signiﬁcantly altered in rats treated with 2.0 mg/kg body weight
of CCl4 compared to untreated rats at 24 h after the injection.
On the other hand, ALT and albumin levels were not sig-
nificantly diﬀerent between DMN- and CCl4-treated rats, as
shown in Table 1, indicating that there was no signiﬁcant dif-
ference in hepatocyte damage between DMN and CCl4 intox-
ication in rats. Furthermore, the reduction of plasma
ADAMTS13 activity was dose-dependent in DMN-treated
rats as depicted in Fig. 1B. These results suggest that the dam-
age to hepatic stellate cells may explain the reduction of plas-
ma ADAMTS13 activity in rats with acute liver injury induced
by DMN.
To explore whether acute liver injury does not always cause
reduced ADAMTS13 activity, it was determined in rats with
TAA-induced liver injury [13], where apoptosis was reported
in hepatocytes, but not in hepatic stellate cells [19]. As shown
in Fig. 1A, plasma ADAMTS13 activity was not signiﬁcantly
altered in rats treated with 300 mg/kg body weight of TTA
compared to untreated rats at 48 h after the injection. Serum
ALT and albumin levels in TAA-treated rats were not signiﬁ-
cantly diﬀerent from DMN- or CCl4-treated rats, as shown in
Table 1. Thus, this result suggests that reduced ADAMTS13
activity may not be generally found in acute liver injury and
the selective damage to hepatic stellate cells may be a key to
the reduction of plasma ADAMTS13 activity in rats with
acute liver injury.
Because our previous report showed that hepatic stellate cell
apoptosis was ﬁrst detected at 7.5 h and hepatocyte necrosis at
Fig. 2. Time-course analysis of plasma ADAMTS13 activity in DMN-
treated rats. Rats received an injection of 50 mg/kg body weight of
DMN and were sacriﬁced at 6, 9, and 12 h after the injection.
ADAMTS13 activity in the plasma was measured using an
ADAMTS13 activity ELISA kit. Bars represent the means ± S.D. of
six samples. An asterisk indicates a signiﬁcant diﬀerence between
untreated control and DMN-treated rats (P < 0.05 or higher degree of
signiﬁcance).
Fig. 3. Eﬀect of normal rat plasma supplementation on plasma
ADAMTS13 activity and platelet count in DMN-treated rats. Rats
received an injection of 50 mg/kg body weight of DMN, and 2 ml of
normal rat plasma was administered at 4 and 8 h after the injection.
The plasma ADAMTS13 activity and platelet count were measured at
12 h after the injection. Columns and bars represent the means ± S.D.
of six samples.
Fig. 4. Plasma ADAMTS13 activity in 70% hepatectomized rats. Rats
underwent 70% hepatectomy (Hx) or sham operation (Sham) and were
sacriﬁced at 24 h after the operation. ADAMTS13 activity was
measured in the plasma using an ADAMTS13 activity ELISA kit.
Columns and bars represent the means ± S.D. of ﬁve samples. An
asterisk indicates a signiﬁcant diﬀerence between rats with a sham
operation and 70% hepatectomy (P < 0.05 or higher degree of
signiﬁcance).
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course analysis of plasma ADAMTS13 activity in DMN-in-
duced liver injury. As depicted in Fig. 2, plasma ADAMTS13
activity was reduced in a time-dependent manner; a trend of
reduction was noted at 6 h and a signiﬁcant reduction was
determined at 12 h after DMN injection. Thus, the timing of
the reduction of plasma ADAMTS13 activity appeared to
coincide with the initiation of hepatic stellate cell apoptosis.
These results may be consistent with the hypothesis that hepa-
tic stellate cell apoptosis would cause the reduction of plasma
ADAMTS13 activity in DMN-induced liver injury.
As we previously reported, a markedly reduced peripheral
platelet count was identiﬁed in rats treated with DMN (Table
1) [12,20]. This reduction was attributed to intravascular coag-
ulation in the liver, because ﬁbrin formation was noted in the
hepatic sinusoids and antithrombin treatment inhibited plate-
let count reduction [12,20]. In this study, we raised the ques-
tion of whether reduced plasma ADAMTS13 activity would
play a role in platelet count reduction in DMN-induced liver
injury. To answer this, DMN was injected in rats, and normal
rat plasma at 2 ml was administered at 4 and 8 h and the plate-
let count and plasma ADAMTS13 activity were determined at
12 h after the injection. As shown in Fig. 3, an increase in plas-
ma ADAMTS13 activity in DMN-treated rats with normal rat
plasma administration was noted; however, there was a trend
toward a decreasing platelet count in these rats. This result
may suggest that the reduction of plasma ADAMTS13 activity
did not play a role in the decrease of the peripheral platelet
count in DMN-induced liver injury. It was reported that even
when the ADAMTS13 gene was knocked out, thrombocytope-
nia was not found in mice, suggesting that intravascular
thrombi are not necessarily caused by reduced plasma
ADAMTS13 activity alone [21]. Our results may be in line
with this report, and the relation between reduced plasma
ADAMTS13 activity and thrombi production should be fur-
ther elucidated.
Next, we employed partial hepatectomy in rats to examine
whether the loss of hepatic stellate cells via surgery would leadto reduced plasma ADAMTS13 activity. Fig. 4 demonstrates
that plasma ADAMTS13 activity was signiﬁcantly reduced
in rats with a 70% partial hepatectomy compared to sham-
operated rats. A signiﬁcant decrease in plasma ADAMTS13
activity was also reported in human cases with major hepatec-
tomy [22].
Based on the evidence that hepatic stellate cells are impor-
tant as cells which synthesize ADAMTS13 [10,11], we investi-
gated the possibility that hepatic stellate cells play a role in
determining plasma ADAMTS13 activity in this study. Then,
we clariﬁed that hepatic stellate cell damage via chemical toxin
administration or hepatic stellate cell loss via surgery similarly
causes a reduction in plasma ADAMTS13 activity. Recently, it
was reported that human venous and arterial endothelial cells
synthesize and release ADAMTS13, suggesting that the vast
number of endothelial cells are another important source of
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ings, it is unlikely that there would be a massive amount of
damage caused to endothelial cells or vascular endothelium
not only in the liver but also in the whole body in DMN-trea-
ted or hepatectomized rats, so the reduction of plasma
ADAMTS13 activity is not attributable to endothelial cell or
vascular endothelium damage in those rats.
It is now well known that hepatic stellate cells play a central
role in the development of hepatic ﬁbrosis [25]. In response to
liver damage, hepatic stellate cells transdiﬀerentiate to a myoﬁ-
broblast-like phenotype with enhanced proliferation, ﬁbrogene-
sis and contractility, in which process ADAMTS13 activity was
shown to be increased in vitro and in vivo [26]. Of interest,
ADAMTS13 activity was reported to be increased in the liver
tissue lysate, but not in the plasma in rats with liver ﬁbrosis in-
duced by CCl4 [26]. In patients with liver cirrhosis, ADAMTS13
activity in the plasma is shown to be decreased [27], and in con-
trast, highly variable [28]. Development of ADAMTS13 inhibi-
tor was reported in a patient with hepatitis C virus-related liver
cirrhosis [29]. These studies suggest that the regulatory mecha-
nisms of plasma ADAMTS13 activity may be complicated in
the chronic illness aﬀecting the liver. However, our current evi-
dence with animal experiments of acute liver injuries suggests
that hepatic stellate cells may be involved at least in part in
the regulation of plasma ADAMTS13 activity.References
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